about us
Dedicated to revolutionizing new drug discovery and development
More than 15 years of dedication to revolutionizing new drug therapies
2023
-
06.
IND approval of LCB84(Anti-TROP2 ADC) for phase 1/2
-
12.
LCB enters into Licensing agreement with Janssen for Trop2 ADC
2022
-
01.
Approval of LCB14 (HER2 ADC) phase 2 clinical trial in China
-
04.
LCB enters into In-licensing agreement with Harbour BioMed
-
03.
Established 'AntibodyChem Bioscienses', a subsidiary in Boston, USA
-
09.
LCB14 'World ADC summit' clinical phase 1 interim data released
-
11.
LCB and NextCure in the US Enter into Co-Development Agreement to Develop ADC
-
11.
Delpazolid, designated as an orphan drug by the EMA
-
11.
SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences
-
12.
LCB and Amgen enter into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
2021
-
05.
LCB enters into In-licensing agreement with Mediterranea Theranostic for Trop-2 antibody
-
06.
LCB and Iksuda Enter Into a expansion of License Agreement for the Development of Antibody-Drug Conjugates
-
10.
Awarded 'Best ADC Platform Technology' for 4 consecutive years at'World ADC Awards 2021'
-
11.
LCB and Sotio Enter Into a Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates
-
12.
LCB and IKSUDA enter Co-development & License Agreement for Antibody Drug Conjugate program (anti-HER2 ADC)
2020
-
12.
LCB enters into research Licensing agreement with a leading japanese pharmaceutical company
-
12.
LCB enters into Licensing agreement with Pyxis for DLK1 ADC
-
-
10.
LCB enters into Licensing agreement with CStone for Anti-ROR1 ADC
-
-
10.
Awarded 'Best ADC Platform Technology' for 3 consecutive years at'World ADC Awards 2020'
-
05.
LCB enters into Licensing agreement with Iksuda for Anti-CD19 ADC
-
-
04.
LCB enters into Licensing agreement with Iksuda for ADC platform technology
-
2019
-
10.
Awarded the 'Best ADC Platform Technology' for two consecutive years at World ADC Awards 2019
-
06.
Registered the patent for an exclusive ADC platform technology 'ConjuALL' in the United States
-
03.
LCB enters into Licensing agreement with Takeda for ADC platform technology
-
2018
-
01.
LCB enters into third party Licensing agreement with Lee's Pharm for LCB02-0133
-
01.
Delpazolid designated for Fast Track by US FDA
2017
-
08.
Japanese patent registration on the unique ADC platform technology ConjuALL
-
07.
Delpazolid designated for Orphan Drug by US FDA
-
05.
LCB enters into third party Licensing agreement with BridgeBio for BBT-877
-
04.
US patent registration on the unique ADC platform technology ConjuALL
-
01.
Patent acquisition on LegoChem Bio, ADC antibody structure and manufacturing method
-
01.
LCB enters into research licensing agreement with Takeda
2016
-
12.
LCB enters licensing agreement with RMX Biopharma for LCB01-0371 (gram-positive antibiotic) regarding China market.
-
08.
LCB Initiates clinical trial phase I of oxazolidinone antibiotic LCB01-0371 (IV)
-
07.
LCB sets up a Joint Venture for the global development of Cephalosporin antibiotic LCB10-0200
-
06.
LCB obtains patent for its novel linker chemistry (Compounds Comprising Self-immolative group)
-
05.
LCB initiates clinical trial phase II of oxazolidinone antibiotic LCB01-0371 (PO)
-
05.
Mechanical completion of API Plant I (LegoChem Pharma)
-
08.
LCB extends designation as “K-Brain Power” Company by the Ministry of Trade, Industry and Energy
2015
-
12.
Acquisition of Khanmed & Hanbul Pharma
-
11.
LCB enters into a Joint Research agreement with Theranyx
-
08.
LCB licenses out anti-Her2 ADC to Fosun Pharma for the Greater Chinese market
2014
-
10.
LCB01-0371 (oxazolidinone antibiotic) is selected as a “PHARM NAVI” project by the MFDS (Ministry of Food and Drug Safety)
-
09.
Completion of clinical trial phase 1 for LCB02-0133 (FXa, Anti-Coagulant Candidate)
-
08.
LCB is designated as “K-Brain Power” Company by the Ministry of Trade, Industry and Energy.
2013
-
08.
LCB Initiates pre-clinical trial of cephalosporin antibiotic LCB10-0200
-
07.
LCB’s ADC (Antibody Drug Conjugate) is selected as an investment related project by the Small and Medium Business Administration (SMBA).
-
05.
LCB (141080) is listed on KOSDAQ through Initial Public Offering
2012
-
12.
LCB enters into a collaboration agreement with AstraZeneca and license out its cephalosporion antibiotic candidate LCB10-0200
-
12.
LCB enters into a collaboration agreement with Green Cross to develop Next-generation Antibody-Drug Conjugates
-
07.
LCB enters into a collaboration agreement with Sanofi to develop novel oncologics
-
06.
LCB designated as an INNO-BIZ company
-
03.
CB named as “Emerging Company of the Year 2012” (BioSpectrum Aisa, Singapore)
-
02.
LCB initiates clinical trial phase I of FXa inhibitor anti-coagulant candidate LCB02-0133
2011
-
11.
US FDA IND approval for anti-coagulant candidate LCB02-0133
-
07.
LCB02-0133(Anit-coagulant, FXa inhibitor) selected as Global New Drug Discovery Project by Korean Ministry of Education, Science, and Technology
2010
-
12.
Completed non-clinical trials of an oxazolidinone antibiotic
-
10.
Signed a joint research contract on anticancer drugs with Interprotein in Japan (Project title: VEGF inhibitor)
-
09.
Presented research findings on antibiotics at 2010 ICAAC in Boston, United States
2009
-
12.
LCB presents antibiotic study result at the 2009 “ICAAC” San Francisco
-
06.
LCB successfully license-out its preclinical stage Anti-coagulant candidate LCB02-0133 (FXa inhibitor)
-
01.
Joint research contract with The Catholic Univ. School of Medicine (ophthalmic medicine: Wondonin) is executed
2008
-
05.
LCB receives Korean MOHW (Ministry of Health and Welfare) researching funding for oxazolidinone antibiotic candidate.
2007
-
09.
LCB presents oxazolidinone antibiotic study result at the Chicago “ICAAC” Conference 2007